MEDP Maintained by UBS -- Price Target Raised to $700

gurufocus.com · 2026-10-23

On October 07, 2026, Medpace Holdings (MEDP) received a maintained neutral rating from UBS analyst Kevin Caliendo. The price target for the stock has been adjus

TickrTrends take: UBS raised its price target for MEDP to 700, maintaining its stance on the stock. Given that TickrTrends currently rates MEDP as overvalued within the Healthcare sector, investors focused on valuation metrics should monitor whether the analyst's higher price target reflects genuine fundamental improvements or if the stock continues to trade above levels justified by underlying business metrics. The divergence between analyst optimism and TickrTrends' overvaluation assessment highlights the importance of examining the specific drivers behind UBS's target adjustment.

Read the full story at gurufocus.com →